Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Twelve Guidances For High-Priority FDAMA Provisions Released By CDRH

This article was originally published in The Gray Sheet

Executive Summary

Early revisions to 12 device guidance documents implementing high-priority provisions of the FDA Modernization Act likely will be made only in response to comments from manufacturers or other interested groups, agency staffers say.

You may also be interested in...

Industry Should Prefer Early Collaboration "Agreement" Meetings - Alpert

FDA's propensity to suggest that sponsors hold non-binding "agreement" meetings in lieu of binding "determination" meetings in their pursuit of agency go-ahead is in industry's best interest, Susan Alpert, director of the Center for Devices and Radiological Health's Office of Device Evaluation, maintained.

PBA Announces New Leadership; Honest Company Names CFO; Beauty Executive News

Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts